Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort
Journal of Gastroenterology · 05.11.2026
DOI: 10.1007/s00535-026-02525-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 05.11.2026. Verfasst von Miwa Kawanaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, 2-5-1 Shikata-Cho, Kita-Ku, Okayama City, Okayama, 700…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Fibrosis stage is the strongest histologic determinant of outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), but annualized fibrosis dynamics under routine care remain insufficiently quantified. We characterized fibrosis progression rate (FPR) in a long-term, pre-incretin paired-biopsy cohort to provide reference data for emerging metabolic therapies.
Methods
We analyzed 153 patients with MASLD who underwent repeat liver biopsy at a single center over a median interval of 5.9 years (range, 0.5–24). No patient received a GLP-1 receptor agonist or a dual GLP-1/GIP receptor agonist during follow-up. FPR was defined as the annualized change in fibrosis stage (stage/year). Factors associated with fibrosis improvement were examined using multivariable logistic regression.
Results
Fibrosis improved in 38 patients (25%), remained stable in 66 (43%), and progressed in 49 (32%). FPR varied substantially among patients with improvement or progression, revealing bidirectional and heterogeneous fibrosis dynamics not captured by categorical staging alone. FPR shifted in parallel with MASLD activity score change and was more closely related to changes in hepatocellular ballooning and lobular inflammation than to steatosis. Male sex, advanced baseline fibrosis, and ≥5% body weight reduction were associated with fibrosis improvement, with the likelihood increasing as these factors accumulated.
Conclusion
In this real-world pre-incretin paired-biopsy cohort, fibrosis change under routine care was bidirectional and heterogeneous, with wide variation in annualized rate. These data provide a reference for evaluating how emerging metabolic therapies modify the longitudinal course of MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, 2-5-1 Shikata-Cho, Kita-Ku, Okayama City, Okayama, 700-8558, Japan. m.kawanaka@okayama-u.ac.jp.
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, 2-5-1 Shikata-Cho, Kita-Ku, Okayama City, Okayama, 700-8558, Japan.
- Department of General Internal Medicine 2, Kawasaki Medical School, 2-6-1, Nakasange, Kita-Ku, Okayama City, Okayama, 700-8551, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Kawanaka, M., Miyamoto, K., Murakami, S., Li, J., Liu, Y., Tanaka, E., Miyake, N., Adachi, T., Takeuchi, Y., Onishi, H., Nishino, K., Fushimi, T., Urata, N., Kawamoto, H., & Otsuka, M. (2026). Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02525-y
Vancouver
Kawanaka M, Miyamoto K, Murakami S, Li J, Liu Y, Tanaka E, et al. Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02525-y
BibTeX
@article{Kawanaka2026,
author = {Kawanaka, Miwa and Miyamoto, Kazuya and Murakami, Shiho and Li, Jinpeng and Liu, Ying and Tanaka, Emi and Miyake, Nozomi and Adachi, Takuya and Takeuchi, Yasuto and Onishi, Hideki and Nishino, Ken and Fushimi, Takashi and Urata, Noriyo and Kawamoto, Hirofumi and Otsuka, Motoyuki},
title = {Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-026-02525-y}
}
EUVIMED